Roseburia Intestinalis

Butyrate is what the cells lining your colon burn for fuel, and your own body doesn't make it. Gut bacteria do, by fermenting the fiber you eat. Roseburia intestinalis is one of the two or three species that do most of that work. When it thins out, stool studies of people with inflammatory bowel disease, colorectal cancer, and a long list of inflammatory conditions keep finding the same thing: it is depleted.

This is a research marker, not a diagnosis. There are no standardized cutpoints, no guideline telling you what number to aim for, and no trial showing that measuring it changes what happens to you. What it gives you is a direct read on whether your gut's butyrate machinery is present, which no blood panel or stool calprotectin test will tell you.

What This Bacterium Actually Does

Roseburia intestinalis lives in the colon and dies on contact with oxygen, which is part of why it is hard to grow in a lab and hard to put in a capsule. It breaks down complex dietary starches, and its main output is butyrate. Butyrate is the primary energy source for the cells lining your colon, and it does more than feed them.

In laboratory and animal work, butyrate and other products of this organism tighten the junctions between gut lining cells, calm inflammation in the gut wall, and push immune cells toward a regulatory rather than inflammatory state. That mechanism is why depletion keeps showing up alongside barrier breakdown. Animal studies also show that giving this bacterium directly restores those junction proteins and lowers inflammatory signaling, though nobody has yet run that experiment in people.

So a low result is best read as a signal that your gut's fiber-to-butyrate capacity is diminished. Whether that causes a problem or reflects one is the central open question, and the sections below keep running into it.

Inflammatory Bowel Disease

This is where the human evidence is strongest. Adults and children with Crohn's disease and with active ulcerative colitis consistently show depleted Roseburia in stool compared with healthy controls, and the depletion tracks with how active the inflammation is. In pediatric Crohn's disease, the shortfall is present at diagnosis, before any treatment starts.

The more useful finding is that it shows up early. In a large cohort of healthy first-degree relatives of people with Crohn's disease, gut microbiome composition was associated with who later developed the disease. Separately, healthy adults carrying a high genetic risk score for inflammatory bowel disease already had reduced Roseburia before any symptoms appeared. In a ten-year follow-up of people already diagnosed, microbiome signatures predicted who would need their therapy escalated.

If you have a first-degree relative with Crohn's or colitis, this is the one situation where checking your number is arguably more than curiosity. A low result would not diagnose anything. It would tell you that the ecological pattern seen in people who go on to develop the disease is present in you, which is a reason to watch symptoms closely and to check fecal calprotectin if anything changes.

Colorectal Cancer and Gut Cancers

Stool measurement reliably shows this species depleted in people with colorectal cancer compared with healthy volunteers, and it is depleted in early colorectal growths too, not only in established tumors. In a cohort of people with stage I to III colorectal cancer, higher gut microbiome diversity and a set of specific bacteria were associated with better disease-free survival.

The bacterium alone is not a screening test. In a study of 439 people across two cohorts, individual bacterial markers measured by stool PCR had only moderate discriminating power on their own. Combining four bacterial markers with a fecal immunochemical test caught more cancers than the stool bleeding test alone, at 92.8% sensitivity and 81.5% specificity, but that is a four-marker panel, not this one species.

The same depletion pattern appears in pancreatic cancer, where a small study found levels roughly 500-fold lower in patients than in controls. In gastric cancer, lower Roseburia predicted whose cancer spread to the lining of the abdomen. These are small, cross-sectional studies. They tell you the pattern is real and consistent; they do not make this a cancer test.

Practically: a low result is not a reason to panic about cancer, and a normal result is not a reason to skip colonoscopy or your fecal immunochemical test. Age-appropriate colorectal screening stands on its own and this does not substitute for it.

Beyond the Gut

Depletion turns up in a long list of conditions outside the intestine. A meta-analysis of shotgun sequencing studies in Parkinson's disease found Roseburia consistently reduced across cohorts from different countries. People with amyotrophic lateral sclerosis have lower levels of butyrate-producing bacteria than controls. Reduced abundance also appears in rheumatoid arthritis, anorexia nervosa, atherosclerosis, and end-stage kidney disease.

Two findings are more concrete than the rest. In acute ischemic stroke, people with minor strokes had more Roseburia than those with severe ones, and depleted Roseburia independently predicted who developed pneumonia after the stroke. In inflammatory bowel disease complicated by arthritis, women with the joint involvement had lower Roseburia intestinalis in the gut lining than those without it.

Read this list for what it is. A species that disappears in this many unrelated illnesses is probably responding to something common to all of them: body-wide inflammation, changed transit time, or the diet shifts that come with being sick. That does not make it useless. It makes it a general signal that the gut ecosystem has been disturbed rather than a marker pointing at any one disease.

The Metabolic Picture Is Not Simple

Across observational studies, lower Roseburia goes with metabolic syndrome, larger waist circumference, and higher type 2 diabetes risk. Higher levels track with lean body composition and lower fasting glucose. The obvious reading is that more is better.

Then the evidence turns. A Mendelian randomization study, which uses inherited genetic variation to test whether a relationship is causal rather than coincidental, found that genetically higher Roseburia abundance was associated with slightly higher odds of type 2 diabetes, not lower. Overweight and obese pregnant women with ketones in their urine had more Roseburia, not less. In a study of overweight adults, higher body mass index went with more of it in people without back pain.

These findings only look contradictory if you treat this as a good-number-bad-number marker. It isn't one. Abundance reflects how much fermentable material reaches your colon and how efficiently it gets harvested, and that capacity can be favorable in one context and unremarkable in another. Depletion in someone with active inflammation means something different from abundance in someone eating a lot of fermentable carbohydrate. Read the number alongside what else is going on in your body, not as a score.

Why a Single Reading Is Unreliable

This is the thing to know before you order the test. Day-to-day variation within the same person is large. The swing between two samples from one individual days apart can be as big as the change an intervention produces. Diet in the days before collection, transit time, and stool consistency all move the number.

The lab side is more reliable than the biology. Quantitative PCR reproduces well across repeat portions of the same sample. The noise comes from the gut, not the machine.

So get a baseline, and if you are changing something, retest after at least four weeks rather than after a few days. Short bouts of an intervention often produce shifts that resolve on their own: in the exercise literature, only programs of eight weeks or more produced stable change. Keep your diet roughly typical in the days before each collection, and collect at the same point in your routine each time. Two samples a week apart at baseline give you a far better read than one, because you see your own range rather than a single point inside it.

What Can Throw Off a Reading

• Recent antibiotics: a week of amoxicillin-clavulanate depleted Roseburia in a controlled trial, and levels had only partly recovered two weeks later. Wait at least a month after finishing a course before testing, longer if you can.
• An unusual few days of eating: a stretch of low fiber, a restrictive diet, or a big change in fermentable carbohydrate intake shifts this number within days. It is a real biological shift, but it is not your baseline.
• Acute illness or a flare: inflammation, a damaged gut lining, and the appetite changes that come with being unwell all knock down oxygen-sensitive bacteria like this one. A result taken during a flare tells you about the flare, not about your usual state.
• Lab-to-lab differences: relative abundance from sequencing and absolute cell counts from quantitative PCR are not interchangeable numbers. Compare results only against the same lab using the same method.

What to Do With an Unexpected Result

Start by confirming it. Repeat the measurement a few weeks later, under conditions you controlled, before treating one low value as real. Given the day-to-day swing, a single low reading in someone with no symptoms is more likely noise than signal.

If low levels hold up and you have gut symptoms, the useful next step is testing that measures inflammation directly. Fecal calprotectin tells you whether inflammatory immune cells are spilling into your gut, which no bacterial count can. A fecal immunochemical test looks for bleeding. C-reactive protein reads body-wide inflammation. Ordering these alongside your microbiome result is what turns an ecological observation into a picture a gastroenterologist can act on.

Low Roseburia with normal calprotectin and no symptoms is a watch-and-retest situation. Low Roseburia with raised calprotectin, or with persistent diarrhea, blood, or unexplained weight loss, is a reason to see a gastroenterologist and consider a look inside with a scope. Low Roseburia in someone whose parent or sibling has Crohn's disease is the middle case: worth tracking, worth a low threshold for checking calprotectin if symptoms appear. If your levels look fine and your symptoms persist, this result rules nothing out, and the workup proceeds the same way it would have.